PMID- 31547097
OWN - NLM
STAT- MEDLINE
DCOM- 20200210
LR  - 20200210
IS  - 1660-3397 (Electronic)
IS  - 1660-3397 (Linking)
VI  - 17
IP  - 10
DP  - 2019 Sep 20
TI  - The Potential of Neoagaro-Oligosaccharides as a Treatment of Type II Diabetes in 
      Mice.
LID - 10.3390/md17100541 [doi]
LID - 541
AB  - Type 2 diabetes mellitus (T2DM) accounts for more than 90% of cases of diabetes 
      mellitus, which is harmful to human health. Herein, neoagaro-oligosaccharides 
      (NAOs) were prepared and their potential as a treatment of T2DM was evaluated in 
      KunMing (KM) mice. Specifically, a T2DM mice model was established by the 
      combination of a high-fat diet (HFD) and alloxan injection. Consequently, the 
      mice were given different doses of NAOs (100, 200, or 400 mg/kg) and the 
      differences among groups of mice were recorded. As a result of the NAOs 
      treatment, the fasting blood glucose (FBG) was lowered and the glucose tolerance 
      was improved as compared with the model group. As indicated by the 
      immunohistochemistry assay, the NAOs treatment was able to ameliorate hepatic 
      macrovesicular steatosis and hepatocyte swelling, while it also recovered the 
      number of pancreatic beta-cells. Additionally, NAOs administration benefited the 
      antioxidative capacity in mice as evidenced by the upregulation of both 
      glutathione peroxidase and superoxide dismutase activity and the significant 
      reduction of the malondialdehyde concentration. Furthermore, NAOs, as presented 
      by Western blotting, increased the expression of p-ERK1/2, p-JNK, NQO1, HO-1, and 
      PPARgamma, via the MAPK, Nrf2, and PPARgamma signaling pathways, respectively. In 
      conclusion, NAOs can be used to treat some complications caused by T2DM, and are 
      beneficial in controlling the level of blood glucose and ameliorating the damage 
      of the liver and pancreatic islands.
FAU - Lin, Fudi
AU  - Lin F
AD  - College of Chemical Engineering, Huaqiao University, Xiamen 361021, China. 
      15105966539@163.com.
FAU - Yang, Dongda
AU  - Yang D
AD  - College of Chemical Engineering, Huaqiao University, Xiamen 361021, China. 
      17359896913@163.com.
FAU - Huang, Yayan
AU  - Huang Y
AD  - College of Chemical Engineering, Huaqiao University, Xiamen 361021, China. 
      yyhuang@hqu.edu.cn.
FAU - Zhao, Yan
AU  - Zhao Y
AD  - College of Chemical Engineering, Huaqiao University, Xiamen 361021, China. 
      18404985982@163.com.
FAU - Ye, Jing
AU  - Ye J
AD  - College of Chemical Engineering, Huaqiao University, Xiamen 361021, China. 
      yejenny@hqu.edu.cn.
AD  - Xiamen Engineering and Technological Research Center for Comprehensive 
      Utilization of Marine Biological Resources, Xiamen 361021, China. 
      yejenny@hqu.edu.cn.
FAU - Xiao, Meitian
AU  - Xiao M
AD  - College of Chemical Engineering, Huaqiao University, Xiamen 361021, China. 
      mtxiao@hqu.edu.cn.
AD  - Xiamen Engineering and Technological Research Center for Comprehensive 
      Utilization of Marine Biological Resources, Xiamen 361021, China. 
      mtxiao@hqu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20190920
PL  - Switzerland
TA  - Mar Drugs
JT  - Marine drugs
JID - 101213729
RN  - 0 (Antioxidants)
RN  - 0 (Blood Glucose)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Oligosaccharides)
RN  - 0 (PPAR gamma)
SB  - IM
MH  - Animals
MH  - Antioxidants/metabolism
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Diet, High-Fat/adverse effects
MH  - Insulin-Secreting Cells/drug effects/metabolism
MH  - Liver/drug effects/metabolism
MH  - Male
MH  - Mice
MH  - NF-E2-Related Factor 2/metabolism
MH  - Oligosaccharides/*pharmacology
MH  - PPAR gamma/metabolism
MH  - Signal Transduction/drug effects
PMC - PMC6835453
OTO - NOTNLM
OT  - MAPK
OT  - Nrf2
OT  - PPARgamma
OT  - neoagaro-oligosaccharides
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2019/09/25 06:00
MHDA- 2020/02/11 06:00
PMCR- 2019/10/01
CRDT- 2019/09/25 06:00
PHST- 2019/08/18 00:00 [received]
PHST- 2019/09/10 00:00 [revised]
PHST- 2019/09/16 00:00 [accepted]
PHST- 2019/09/25 06:00 [entrez]
PHST- 2019/09/25 06:00 [pubmed]
PHST- 2020/02/11 06:00 [medline]
PHST- 2019/10/01 00:00 [pmc-release]
AID - md17100541 [pii]
AID - marinedrugs-17-00541 [pii]
AID - 10.3390/md17100541 [doi]
PST - epublish
SO  - Mar Drugs. 2019 Sep 20;17(10):541. doi: 10.3390/md17100541.